Clinical trials: Colorectal Cancer Metastatic to Liver
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
- Trial name
- NCT06856837
- Testing
- Fruquintinib, Tislelizumab, Trifluridine/tipiracil
- Where
- 23 sites in Austria, Germany
- Volunteers
- 140 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Colorectal Cancer
Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer
The metastatic colon cancer is a major public health problem despite advances in chemotherapy; few new drugs are in development for the treatment of this pathology.
- Trial name
- IRAFU (NCT02090101)
- Testing
- ANAKINRA
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Georges Francois Leclerc
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Colorectal Cancer, Colon Cancer Liver Metastasis
Diffusion-Weighted MRI for Liver Metastasis
The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination with other imaging modalities (multiparametric MRI and CT Scan) in determining the true status of disappearing liver metastasis (DLM)…
- Conditions
- Colorectal Cancer, Colon Cancer Liver Metastasis, Malignant Neoplasm of Rectum Metastatic to Liver
- Trial name
- DREAM (NCT02781935)
- Testing
- DW-MRI
- Where
- 21 sites in United States, Austria and 3 more
- Volunteers
- 233 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Colo-rectal Cancer
LOTCOL Study: Local Treatment of Colo-rectal Liver Met
In this study the investigators will include colo-rectal cancer (CRC) patients starting last line of standard palliative chemotherapy.
- Trial name
- LOTCOL (NCT01867918)
- Testing
- Radiofrequency ablation, microwave, radiation therapy, Standard Chemotherapy
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- Oslo University Hospital
Metastatic Colorectal Cancer
HepaSphere™ Microspheres Prospective Registry
HepaSphere™ Microspheres loaded with irinotecan received CE mark for the indication of use in embolization of metastatic colorectal cancer (mCRC) to the liver in 2015.
- Trial name
- mCRC (NCT04866290)
- Testing
- HepaSphere Microspheres
- Where
- 2 sites in France, Greece
- Volunteers
- 105 people
- Sponsor
- Merit Medical Systems, Inc.
Prehabilitation, Neoadjuvant Therapy
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
Liver resection is the only curative treatment for patients with colorectal liver metastases (CRLM). Most patients undergo chemotherapy (CT) before liver surgery. CT objectively decreases patient functional capacity.
- Conditions
- Prehabilitation, Neoadjuvant Therapy, Liver Metastases
- Trial name
- PREHABMET (NCT04520737)
- Testing
- Physical Prehabilitation
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Liver Resection, Colorectal Carcinoma Liver Metastases
Safety of HRX215 in Patients After Minor and Major Liver Resection
The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1.
- Trial name
- NCT06638502
- Testing
- HRX215 capsules
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 80 people
- Sponsor
- HepaRegeniX GmbH
Carcinoma, Hepatocellular, Colorectal Neoplasms
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the…
- Conditions
- Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma, Kidney Neoplasms
- Trial name
- NCT02439008
- Testing
- Blood samples collection before radiotherapy, Blood samples collection during radiotherapy, Blood samples collection after radiotherapy
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Colon Carcinoma, Rectum Carcinoma
L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases
Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).
- Trial name
- LICC (NCT01462513)
- Testing
- L-BLP25
- Where
- 21 sites in Austria, Germany
- Volunteers
- 122 people
- Sponsor
- Prof. Dr. Carl Schimanski
Colorectal Cancer Metastatic
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression…
- Trial name
- HAITI (NCT06332079)
- Testing
- 166Holmium TARE, Cetuximab, Panitumumab
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
Cancer of Colon, Metastasis to Liver
Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer
Analyze the dynamics of incorporation of 5-fluorouracil into cancer cell ribosomes from liver metastases of patient with metastatic colon cancer.
- Trial name
- FLUORIB (NCT04274790)
- Testing
- Scheduled and planned surgery
- Where
- France
- Sponsor
- Centre Leon Berard
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Colorectal Neoplasm, Liver Neoplasm
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan.
- Conditions
- Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00001576
- Testing
- Melphalan, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)